Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.

Antimicrobial agents and chemotherapy - 1 Apr 2016

Giandhari Jennifer, Basson Adriaan E, Sutherland Katherine, Parry Chris M, Cane Patricia A, Coovadia Ashraf, Kuhn Louise, Hunt Gillian, Morris Lynn

Abstract excerpt

Protease inhibitors (PIs) are used as a first-line regimen in HIV-1-infected children. Here we investigated the phenotypic consequences of amino acid changes in Gag and protease on lopinavir (LPV) and ritonavir (RTV) susceptibility among pediatric patients failing PI therapy. The Gag-protease from isolates from 20 HIV-1 subtype C-infected pediatric patients failing an LPV and/or RTV-based regimen was phenotyped...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Gene Products, gag

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to Mutagenesis, Site-Directed

Share to Ritonavir

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 26833162
DOI: 10.1128/AAC.02682-15
PMCID: PMC4808165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.PMID 26833162Read ↗

Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.Semantic proximity Read ↗

Mutations in the reverse transcriptase and protease genes of human immunodeficiency virus-1 from antiretroviral naïve and treated pediatric patients.Semantic proximity Read ↗

Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.Semantic proximity Read ↗

Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1Semantic proximity Read ↗

HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience.Semantic proximity Read ↗

Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy.Semantic proximity Read ↗

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.Semantic proximity Read ↗

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced PatientsSemantic proximity Read ↗

Viral resistance to protease inhibitors.Semantic proximity Read ↗

Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.Semantic proximity Read ↗

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.Semantic proximity Read ↗

Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.